Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This research study is designed to test the use of ranolazine in patients with angina (chest
discomfort due to reduced blood supply to the heart) due to microvascular coronary
dysfunction (MCD; abnormalities in the small blood vessels of the heart). This drug is
approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina. The
FDA has approved this drug based on studies primarily on patients with chronic angina with
major blockages of the arteries.